Forty Seven Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Forty Seven Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 11 Jul 2019 | Lorem |
| Forty Seven’s 5F9 Phase Ib/II in r/r NHL has experts confident of the drug’s safety profile, despite initial anemia concerns with CD47 target | 03 Apr 2019 | Mariana Lenharo |
| Forty Seven to welcome CRO pitches in early 2019 for Phase II and III trials of anti-CD47 antibody, executive says | 21 Nov 2018 | Mariana Lenharo |
| Forty Seven plans two CD47 antibody Phase Ib trials by YE16 - executive | 29 Feb 2016 | Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer